Company news
Enzolytics Inc. (OTC:ENZC) news
Enzolytics Inc. news releases on 6ix. Latest, Sep 22, 2025: ENZC Receives Letter of Support
Press releases & updates
ENZC Receives Letter of Support
September 21, 2025
Enzolytics announces New Ceo and 500 to 1 Reverse Split
June 3, 2025
ENZOLYTICS REFUTES CLAIMS
June 3, 2025
Creatd, Inc. (OTC: CRTD) Completes Initial Stock Swap with Enzolytics, Inc. (OTC: ENZC) in Strategic Transaction
January 24, 2025
ENZOLYTICS, INC. ANNOUNCES IMPLEMENTATION OF CAPITAL RESTRUCTURING PLAN AS PART OF ONGOING ACQUISITION STRATEGY OFFERS UPDATE ON SAGALIAM ACQUISITION CORP
November 5, 2024
Enzolytics, Inc. Addresses Additional Misinformation
October 23, 2024
Enzolytics Inc. Response to Competitor’s Continuing False and Misleading Statements Regarding Zhabilov Trust Patents Statements were Included in NIKA Pharmaceuticals June 30, 2024 10-Q filed with SEC
October 13, 2024
ENZOLYTICS, INC. AND DEPARTMENT OF IMMUNOLOGY, INSTITUTE OF MICROBIOLOGY, BULGARIAN ACADEMY OF SCIENCES BEGINS PROJECT FOCUSING ON DEVELOPMENT OF MELANOMA VACCINE
October 6, 2024
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
September 17, 2024
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
September 8, 2024
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
August 19, 2024
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
July 30, 2024
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
July 28, 2024
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
July 25, 2024
SAGALIUM RESPONDS TO COMPETITOR’S FALSE AND MISLEADING PRESS RELEASE
July 24, 2024
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
June 30, 2024
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
June 2, 2024
Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation
May 21, 2024
ENZOLYTICS, INC. ANNOUNCES LETTER OF INTENT FOR EXCLUSIVE LICENSING AGREEMENT FOR PATENTED NITRIC OXIDE FORMULATION
May 21, 2024
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
May 1, 2024
ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD
March 24, 2024
Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity
January 15, 2024
Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure
November 19, 2023
Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
September 17, 2023
SAGALIAM ACQUISITION CORP. ANNOUNCES EXECUTION OF DEFINITIVE BUSINESS COMBINATION AGREEMENT AND RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER
September 14, 2023
Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")
September 5, 2023
Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.
September 4, 2023
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
August 23, 2023
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
August 7, 2023
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes
August 3, 2023
CORRECTION FROM SOURCE: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC
July 23, 2023
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 and Diabetic Clinical Trials
July 23, 2023
Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease.
July 20, 2023
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
July 10, 2023
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical Trials
July 5, 2023
Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.
June 28, 2023
Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project
June 25, 2023
Enzolytics Offers Update on Virogentics and Sale Transaction, Clinical Trials Progress on European Medicine Agency (EMA) Permitting and Arican ITV-1 Project
June 4, 2023
Virogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science Review
May 18, 2023
Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023
May 15, 2023
Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line
May 7, 2023
Enzolytics Inc. Continues Progress with Business Combination; Biogenysis Announces Team and Plans for Success
April 26, 2023
Enzolytics, Inc. Finalizing Regulatory Labeling Requirements for Delivery of ITV-1 Treatments for Use in Hospitals in Central and Eastern Africa - Company also Provides Additional Details on the Sale of Biogenysis and Virogentics
April 20, 2023
Enzolytics, Inc. Announces Execution of Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp. and Updates the Progress on the African Project
April 16, 2023
Enzolytics Announces Progress in the Development and Patenting of Feline Leukemia Monoclonal Antibodies
April 3, 2023
Enzolytics, Inc. Highlights Plans for Promotion of IPF Immune(TM), Its Patented Nutraceutical Supplement
February 27, 2023
Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa
February 7, 2023
Enzolytics to Develop Feline Monoclonal Antibodies
January 2, 2023
Enzolytics, Inc. Announces the Completion of the 2020 and 2021 Audited Financials
December 18, 2022
Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms
December 12, 2022